Uluru appoints new board member
This article was originally published in Scrip
Uluru (US), a speciality company focused in the development of wound management and oral care products using its novel transmucosal delivery system and its Nanoflex Aggregate technology, has appointed Dr Jeffrey Niezgoda to its board. Dr Niezgoda is the medical director of the Centers for Comprehensive Wound Care and Hyperbaric Oxygen Therapy at St Luke's Medical Center in Milwaukee, US.
You may also be interested in...
Novartis’s AveXis unit has received a CHMP nod for the spinal muscular atrophy gene therapy at its latest meeting, sending it on the final steps to market in the EU.
The arrival of SARS-CoV-2 has focused attention on a potential new way of making vaccines – one that promises to be quicker and cheaper than traditional methods and more reactive to novel virus outbreaks, but also one that remains to be validated.
The German biotech firm has denied receiving any offer from the Trump administration in a wide-ranging conference call that also addressed recent changes at the top, its clinical timeline for a coronavirus vaccine and new funds from the European Commission to boost production.